tbuckley/cabot-search huggingface dataset:
Interepisode consistency of dexamethasone suppression test results in affective disorders
Authors: D A Brizer, R P Brown, J H Kocsis, P E Stokes
Journal: American Journal of Psychiatry (1986)

Twenty-two patients with recurrent affective disorders received 1-mg dexamethasone suppression tests (DSTs) during multiple hospitalizations. Interepisode consistency of DST results was found in 82% of the subjects, which supports the use of this test as a predictor of relapse.
A 23-year-old woman with panic disorder treated with psychodynamic psychotherapy [clinical conference]
Authors: B Milrod, F N Busch, E Hollander, A Aronson, L Siever
Journal: American Journal of Psychiatry (1996)

York, NY I 0021. lasted for 20 minutes and then gradually abated over the better part of an hour. Ms. A did not think of her panic as a reason for seeking psychiatric treatment. She did not have agoraphobia but lived with a chronic, vague sense of severe anxiety, accompanied by the fantasy that she was “doomed.” She had no specific phobias. The symptom that caused Ms. A the most distress was her chronic difficulty negotiat. ing relationships with others. Beginning with her earliest relationships with her parents and older sister in childhood, Ms. A found herself in interpersonal situations in which she felt abused and demeaned, either emotionally or physically. In high school and college she had often felt belittled by friends and boyfriends. Currently, these issues recurred in the context of her relationship with her fianc#{233} and her interactions with colleagues at graduate school. In the course of these stormy relationships, Ms. A would become so agitated and panicked that she was often violent. In the middle of fights with her fianc#{233}, for example, she would find herself hitting him and running out of the apartment dressed in insufficient clothing in the middle of the night. She had no vegetative symptoms. She had no history of depression, mania, psychosis, or substance abuse. She had never been suicidal. Ms. A’s medical history was considered noncontributory.
Abstract IA08: PI3K- and PARP-inhibitors for the treatment of women cancers.
Authors: Gerburg M. Wulf, Ashish Juvekar, Lewis C. Cantley, Ursula A. Matulonis
Journal: Clinical Cancer Research (2016)

Abstract Amplification of PIK3CA is highly prevalent in ovarian cancer and isoform-specific and pan-PI3K inhibitors have entered clinical trials. However, identifying tumor subtypes and biological mechanisms that predict for response to PI3K inhibitors as single agents or in combination has been a challenge. We previously reported that combining a phophoinositide 3-kinase (PI3K) inhibitor with a poly ADP ribose polymerase (PARP)-inhibitor enhanced DNA damage and cell death in breast cancers that have genetic aberrations in BRCA1 and TP53. We now show that the enhanced DNA damage induced by PI3K inhibitors in this mutational background is a consequence of impaired production of deoxynucleotides needed for DNA synthesis and DNA repair. Inhibition of PI3K causes a reduction in all four deoxynucleotide triphosphates (dATP, dTTP, dGTP and dCTP), while inhibition of AKT is less effective than inhibition of PI3K in suppressing nucleotide synthesis and inducing DNA damage. Carbon flux studies reveal that PI3K-inhibition disproportionately affects the non-oxidative pentose phosphate pathway (non-ox PPP) that delivers ribose-5-posphate required for base ribosylation. In vivo in a mouse model of BRCA1-linked triple-negative breast cancer combined PI3K- and PARP-inhibition was superior to either agent alone to induce durable remissions of established tumors. Our data indicate that PI3K inhibitors induce DNA damage in tumors that have defects in DNA damage repair pathways and that they do so by impairing the production of Ribose-5-phosphate and amino acids needed for deoxynucleotide synthesis. An ongoing phase I/II study (NCT01623349, PI: Matulonis) examines the safety and toxicity of a PI3K/Parp-inhibitor combination in ovarian and breast cancer. Citation Format: Gerburg M. Wulf, Ashish Juvekar, Lewis C. Cantley, Ursula A. Matulonis. PI3K- and PARP-inhibitors for the treatment of women cancers. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr IA08.
Ultrafiltration in Heart Failure with Cardiorenal Syndrome
Authors: Gian Paolo Rossi, Antonio Piccoli, Lorenzo A Calò
Journal: New England Journal of Medicine (2013)

To the Editor: Bart et al. (Dec. 13 issue)1 report the results of the Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF). They state that ultrafiltration was inferior to a strategy of stepped pharmacologic therapy with respect to the bivariate primary end point of the change in the serum creatinine level and body weight in patients with acute decompensated heart failure. In clinical practice, at least in Europe, the use of ultrafiltration would not be considered in patients with average urine outputs of 2.8 liters (on day 1), 3.4 liters (on day 2), 3.3 liters (on day 3), and 2.8 liters (on day 4) during medical therapy (see Fig. S3 in the Supplementary Appendix, available with the full text of their article at NEJM.org) and a baseline serum creatinine concentration of approximately 2 mg per deciliter. Ultrafiltration presumably should be restricted to patients with impairment of renal function, cardiac function, or both that is more severe than the impairment in patients involved in the current trial. Furthermore, it is unclear at first sight why renal function should be different at 96 hours only when serum creatinine concentrations are used as a marker of renal function, but not when the level of cystatin C or the glomerular filtration rate are used. How can this discrepancy be explained?
Endocytosis of fibrinogen into megakaryocyte and platelet alpha- granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa) [published erratum appears in Blood 1993 Nov 1;82(9):2936]
Authors: P Handagama, RM Scarborough, MA Shuman, DF Bainton
Journal: Blood (1993)
Case of Placenta Praevia
Authors: H. E. Walker
Journal: BMJ (1845)

PLACENT-A PR&VIA. 557-ing death; to which she unhesitatingly replied, "To the best of tny knowledge I really did swallow, at twice, altogether more than lhalf a tablespoonful, expecting it would very soon kill me."I once related a case, (Lancet, vol. 1, 1836-1837, page 401,) in wbich a girl was seen drinking thirty grains of the red nitric oxide of mercury, fromi which sbe recovered, as I thought, from the use of the stomach-pump.March 29th.The favourite brother of the girl who took arsenic, told me to-day that, agreeably with my request, he has endeavoured to elicit the truth from her, and that he believes she has statted simple facts.
Tick-borne encephalitis: rounding out the picture
Authors: FX Heinz
Journal: Eurosurveillance (2008)

What is now known as tick-borne encephalitis (TBE) was first recognised as a distinct disease entity in 1931 in Europe by H. Schneider and described as 'meningitis serosa epidemica' of unknown etiology. A disease with similar clinical symptoms was reported in the Far East in 1934 and briefly thereafter - in 1937 - the etiologic agent was isolated in Russia and its transmission by ticks could also be demonstrated.
Induction of Neoplasms by Injection of Tumor Chromatin<xref ref-type="fn" rid="fn1">1</xref>, <xref ref-type="fn" rid="fn2">2</xref>
Authors: K. E. Paschkis, M.D., A. Cantarow, M.D., J. Stasney, M.D.
Journal: JNCI Journal of the National Cancer Institute (1955)

Induction of Neoplasms by Injection of Tumor Chromatin, Get access K. E. Paschkis, M.D., K. E. Paschkis, M.D. Division of Endocrine and Cancer Research, Jefferson Medical College, Philadelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Cantarow, M.D., A. Cantarow, M.D. Division of Endocrine and Cancer Research, Jefferson Medical College, Philadelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Stasney, M.D. J. Stasney, M.D. Division of Endocrine and Cancer Research, Jefferson Medical College, Philadelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1525–1532, https://doi.org/10.1093/jnci/15.Supplement_5.1525 Published: 01 April 1955
Soundings: Seeing things
Authors: Trisha Greenhalgh
Journal: BMJ (2005)

A few months back, I couldn't shake off a chest infection. I self medicated with amoxycillin and then consulted my general practitioner, who prescribed a second line antibiotic. I swallowed the first tablet there and then, and drove on to work.

I remember thinking it strange that the road ahead was covered in shimmering patches of the kind you see on long straight roads in the heat of summer. After all, it was the North Circular Road in November.

A black cat with a shimmering tail leapt out into the road from my left, sprang across to the opposite pavement, and then disappeared behind a bus queue. One of his nine lives.

A few yards farther on, a black cab pulled out from a side road and cut right across me. It changed direction in the middle of the road, and pulled neatly into a parking space on the opposite side. I turned my head to give the driver a dirty look. No black cab—and no parking space.

I pulled into a lay-by and scanned the solid skyline of London rooftops as a seasick sailor might fix her dizzy eyes on the horizon. A black figure in a shimmering cloak leapt deftly from chimney to chimney. Batman. So he was in this too. He and the shimmering spider that was making its way across my windscreen.

Having seen what I saw, I suspect that the physiological mechanism was some sort of short circuiting of the cone cells in my retina, producing black blodge signals that my occipital cortex did its best to convert to complex images. My medical record is now flagged with an idiosyncratic reaction to the antibiotic. The British National Formulary already lists “hallucinations” as a known side effect.

Most powerful drugs have a long list of rather bland adverse effects like “loss of taste,” “skin reactions,” “abdominal cramps,” and the like. Would richer descriptions help us detect these earlier? Many of the victims of paroxetine withdrawal described a sensation of “electric head,” which was logged by the Medicines Control Agency as “paresthesiae,” thereby losing the essence of its distinctiveness. Isn't it time someone set up a Database of Unlikely Sensations in Takers of Medicines with a view to systematically capturing the symptoms we should be warning our patients to look out for?
Family environment as a predictor of psychiatric rehospitalization
Authors: D Spiegel, T Wissler
Journal: American Journal of Psychiatry (1986)

The Family Environment Scale scores and demographic characteristics of 108 discharged psychiatric patients were used to predict outcome at 3 months and 1 year. Higher ratings of family expressiveness predicted fewer days of rehospitalization, especially among schizophrenic patients. Higher family cohesion scores predicted better family-rated patient adjustment. The patients were more likely to rate themselves as better adjusted if they had higher incomes, lived with parents rather than a spouse, and came from families with less emphasis on independence. Family environment was a better predictor of rehospitalization than baseline ratings of clinical status, indicating the importance of family support in the community adjustment of chronic psychiatric patients.
Histological Study of the Destruction and Regeneration of the Gastric Mucous Barrier Following Application of Eugenol. Preliminary Report&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn3"&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/xref&gt;
Authors: Franklin Hollander, Ph. D., Rhoda L. Goldfischer, A. B.
Journal: JNCI Journal of the National Cancer Institute (1949)

Histological Study of the Destruction and Regeneration of the Gastric Mucous Barrier Following Application of Eugenol. Preliminary Report Get access Franklin Hollander, Ph. D., Franklin Hollander, Ph. D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Rhoda L. Goldfischer, A. B. Rhoda L. Goldfischer, A. B. Gastroenterology Research Laboratory, The Mount Sinai Hospital, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 2, October 1949, Pages 339–354, https://doi.org/10.1093/jnci/10.2.339 Published: 01 October 1949
Abstract P2-02-08: Initial circulating tumor cell count and venous thrombosis-free interval in the course of metastatic breast cancer
Authors: G Beinse, F Berger, PH Cottu, M-E Dujaric, I Kriegel, M-N Guilhaume, V Dieras, P Beuzeboc, J-Y Pierga, F-C Bidard
Journal: Cancer Research (2016)

Abstract Background: Circulating tumor cells (CTC) count is a major prognostic factor in metastatic breast cancer. It has been also reported to be associated with venous thrombosis in short-term studies on advanced metastatic breast cancer patients. Methods: We assessed whether an early CTC detection (CellSearch®), before the start of the first line chemotherapy, impacts Thrombosis-Free Interval during the whole course of metastatic breast cancer. Electronic medical files of all patients included in the large prospective IC 2006-04 CTC detection study (NCT00898014, Pierga et al, Ann Oncol 2012) and treated at Institut Curie (Paris, France) were manually and automatically searched for thrombosis events in the course of their metastatic breast cancer. Superficial venous thromboses were not taken into account.Thrombosis-Free Interval (TFI) was defined as the first event occuring between venous or arterial thrombosis. Results: In the 142 patients studied, with a median follow-up of 64 months [25-81 months], venous (deep venous thrombosis, pulmonary embolism, catheter thrombosis and portal vein thrombosis) and arterial thrombosis occurred in 21.8% and 4.2% of patients, respectively. Twenty-four (30%) of the 80 patients with ≥1 CTC/7.5ml of blood before the start of first line chemotherapy experienced at least one thrombotic events in the course of their disease, while only 10 (16%) of the 62 CTC-negative patients experienced a similar event (p=0.06). Baseline positive CTC was associated with a higher risk of experiencing a venous or arterial thrombosis (TFI: HR=2.6 [1.2-5.5], p=0.009). The median TFI was 64 months in CTC-positive patients and not reached in CTC-negative patients. Among the other patients characteristics tested at baseline, Performance Status (PS=1 vs PS=0: HR=0.85 [0.4-1.9], p=NS; PS=2 or 3 vs PS=0: HR=3.7 [1.5-8.7], p=0.003) and LDH levels at baseline (LDH&amp;gt;UNL vs LDH&amp;lt;UNL HR=2.4 [1.2-4.9], p=0.012) were also associated with TFI. Conclusions: Metastatic breast cancer patients with ≥1 CTC before the start of chemotherapy are at higher risk of venous thrombosis; the clinical relevance of thrombo-prophylaxis should be investigated in this population. Citation Format: Beinse G, Berger F, Cottu PH, Dujaric M-E, Kriegel I, Guilhaume M-N, Dieras V, Beuzeboc P, Pierga J-Y, Bidard F-C. Initial circulating tumor cell count and venous thrombosis-free interval in the course of metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-02-08.
The European gonococcal antimicrobial surveillance programme, 2009
Authors: M J Cole, M Unemo, S Hoffmann, S A Chisholm, C A Ison, M J van de Laar
Journal: Eurosurveillance (2011)

Neisseria gonorrhoeae antimicrobial susceptibility is monitored in the European Union (EU) and the European Economic Area (EEA) by the European gonococcal antimicrobial surveillance programme (Euro-GASP). Results from 17 EU/EEA Member States in 2009 showed that 5% of isolates had decreased susceptibility to cefixime, an upward trend in the minimum inhibitory concentrations of ceftriaxone and a high prevalence of resistance to ciprofloxacin (63%)and azithromycin (13%). These results are of public health value and highlight the need for healthcare professionals to be aware of possible cefixime treatment failures. Euro-GASP is being implemented in additional EU/EEA Member States to achieve greater representativeness. In addition, Euro-GASP aims to set up a system which will allow biannual reporting of antimicrobial resistance in the EU/EEA, with a transition from centralised towards decentralised testing,and will link epidemiological data to laboratory data to enhance surveillance. The benefits of this approach include more timely detection of emerging trends in gonococcal resistance across the EU/EEA and the provision of a robust evidence base for informing national and European guidelines for therapy.
The role of polysomnography in the differential diagnosis of chronic insomnia
Authors: E A Jacobs, C F Reynolds, D J Kupfer, P A Lovin, A B Ehrenpreis
Journal: American Journal of Psychiatry (1988)

The authors examined the accuracy of the differential diagnosis of chronic insomnia with and without sleep laboratory studies in a consecutive series of 123 patients. All patients were evaluated by means of a sleep/wake log, a sleep habits questionnaire, structured psychiatric and clinical interviews, and a minimum of two consecutive nights of polysomnography. Notwithstanding a high rate of Research Diagnostic Criteria (RDC)-diagnosed psychopathology (63%) in this sample, the major finding was that in 49% of the patients laboratory results added to, refuted, and/or failed to support the clinical impression. This resulted in substantial modification of the initial diagnostic formulation and therefore in increased specificity of diagnosis.
A Novel Approach for Identifying the Heme-Binding Proteins from Mouse Tissues
Authors: Xiaolei Li, Xiaoshan Wang, Kang Zhao, Zhengfeng Zhou, Caifeng Zhao, Ren Yan, Liang Lin, Tingting Lei, Jianning Yin, Rong Wang, Xiaoli Feng, Siqi Liu
Journal: Genomics Proteomics & Bioinformatics (2003)

Heme is a key cofactor in aerobic life, both in eukaryotes and prokaryotes. Because of the high reactivity of ferrous protoporphyrin IX, the reactions of heme in cells are often carried out through heme-protein complexes. Traditionally studies of heme-binding proteins have been approached on a case by case basis, thus there is a limited global view of the distribution of heme-binding proteins in different cells or tissues. The procedure described here is aimed at profiling heme-binding proteins in mouse tissues sequentially by 1) purification of heme-binding proteins by heme-agarose, an affinity chromatographic resin; 2) isolation of heme-binding proteins by SDS-PAGE or two-dimensional electrophoresis; 3) identification of heme-binding proteins by mass spectrometry. In five mouse tissues, over 600 protein spots were visualized on 2-DE gel stained by Commassie blue and 154 proteins were identified by MALDI-TOF, in which most proteins belong to heme related. This methodology makes it possible to globally characterize the heme-binding proteins in a biological system.
Impact of an home-based program of physical activity on chemotherapy induced delayed nausea and on chemotherapy related fatigue.
Authors: Cristiano Oliva, Maria Vietti, Paola Bergnolo, Antonella Boglione, Simona Chiado Cutin, Orietta Dal Canton, Ferdinando Garetto, Davide Ottaviani, Paolo Pochettino, Alessandro Comandone
Journal: Journal of Clinical Oncology (2015)

e20646 Background: Nausea and fatigue are common side-effects of cancer chemotherapy (CT). Management of fatigue includes pharmacological treatments, psycho-educational and exercise programs. Exercise programs probably improve fatigue acting on hypothalamic–pituitary–adrenal axis. We hypothesized that the same mechanism could impact on CT induced delayed nausea (CIDN). Primary objective was to investigate the effects of an home-based program of physical activity on CIDN. Secondary objective was to define the impact on CT related fatigue (CRF). Methods: We enrolled 40 consecutive patients (pts) with breast or colon carcinoma with an adjuvant CT program at least of 4 months. We excluded 8 patients because aged over 75, with hemoglobin levels < 10 g/dl and with neurological and cardiovascular co-morbidities. We evaluated CIDN and CRF in 2 moments: before (T0) and after (T1) the introduction of the physical exercise program. T0 was fixed after 6 weeks of CT and T1 after 15 weeks of CT. CIDN was detected with the MAT scale. CRF was evaluated with FACT scale. After T0 we proposed to all pts an home-based program of physical activity: 30-60 minutes daily of aerobic, resistance and core stability exercises after a specific training lead by a physical therapist. Differences between T0 and T1 were calculated with Bonferroni adjusted paired samples t-test. Results: 32 pts were evaluable (9 m, 23 f). Median age was 56 (39-71). Median ECOG PS was 0 (0-1). 17 pts with breast carcinoma received 6 courses of FEC regimen (Fluorouracil, Epirubicin and Cyclophosphamide), 15 pts with colon cancer were treated with 12 courses of FOLFOX regimen (Oxaliplatin, Fluorouracil and Folinic Acid). Self reported adherence (physical exercises diary) was < 120 minutes/week in 7 pts, 120-300 minutes/week in 14 pts and > 300 minutes/week in 11 pts. Program was appreciated by 66% of pts. In an intention to threat analysis we detected a significant improvement in CIDN (p 0.010) and in CRF (p 0.001). Conclusions: In this study we demonstrated that an home-based program of trained physical activity through the cooperation between oncologists and physical therapists can represent an interesting perspective in the management of CIDN and CRF.
Molecular Signatures of Tumor-Initiating Cells Unveil Wnt Pathway As a Therapeutic Target in Mantle Cell Lymphoma
Authors: Felipe Samaniego, Lalit Sehgal, Frank K Braun, Zuzana Berkova, Jorge E. Romaguera, Michael Wang, M. Alma Rodriguez, Sattva S Neelapu, Rohit Mathur
Journal: Blood (2014)
The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance
Authors: Ting Martin Ma, Jeffrey J. Tosoian, Edward M. Schaeffer, Patricia Landis, Sacha Wolf, Katarzyna J. Macura, Jonathan I. Epstein, Mufaddal Mamawala, H. Ballentine Carter
Journal: European Urology (2016)
Rheumatoid Heart Disease
Authors: S S MISRA, S PRAKASH, S P TEOTIA, P L AGRAWAL
Journal: New England Journal of Medicine (1971)

factor, LDH cells, and protein were investigated.The clinical evaluation and temperature measurements were performed before treatment and on five occasions during the 6-week follow-up, laboratory estimations being done at the beginning and end of the trial.From the above investigations we concluded that there was no difference in the temperature curves in either group and this was confirmed statistically.Pain improved to a statistically significant degree in both groups.Joint mobility-measured in terms of knee flexions per 30 sec.-showed a statistically significant improvement at all follow-up stages in the lavage patients but not in the controls; testing between the two groups showed no significant difference.Similarly, as regards the range of